Table 1. Patients, engraftment, GVHD... | American Society of Hematology

Table 1.

Patients, engraftment, GVHD occurrence, and response to GCV treatment and outcome

Patient no.	Age, y	Diagnosis	Clinical status at time of BMT	Engraftment	GVHD after infusion of GMC			Outcome
Patient no.	Age, y	Diagnosis	Clinical status at time of BMT	Engraftment	Onset date	Grade	Response	Outcome
1	47	HG B-cell lymphoma; prior autologous BMT	Sensitive relapse	Yes	D31	II	CR GCV alone	Death D91, cerebral toxoplasmosis
2	43	Ph⁺ALL	CR1	Yes	—	—	—	Death D129, ALL relapse
3	38	HG B-cell lymphoma	Refractory relapse	Yes	D15	III	CR GCV alone	Death D106, refractory lymphoma
4	49	Myelodysplasia	Refractory	Yes	—	—	—	Death D38, posttraumatic cerebral hemorrhage
5	52	HG B-cell lymphoma	CR2	Yes	—	—	—	Death D72, EBV-LPD + lung aspergillosis
6	41	CML	CP	Yes	D20	II	CR GCV + steroids	Alive 34 months +, CR
7	51	Ph⁺ALL	CR1	Yes, late graft failure^*	—	—	—	Alive 34 months +, CR^†
8	43	CML	CP	Yes	—	—	—	Alive 29 months +, CR
9	43	CML	CP	Yes	D135 CGVHD	—	CR GCV alone^‡	Alive 31 months +, CR^1-153
10	46	CML	CP	Yes, late graft failure^1-155	—	—	—	Death D159, EBV-lymphoma^1-155
11	49	HG B-cell lymphoma	Refractory	Yes	—	—	—	Death D252, acute GVHD^1-154
12	55	Waldenström disease	Refractory	Yes	D40	I#	CR GCV alone	Death D300, sepsis

Patient no.	Age, y	Diagnosis	Clinical status at time of BMT	Engraftment	GVHD after infusion of GMC			Outcome
Patient no.	Age, y	Diagnosis	Clinical status at time of BMT	Engraftment	Onset date	Grade	Response	Outcome
1	47	HG B-cell lymphoma; prior autologous BMT	Sensitive relapse	Yes	D31	II	CR GCV alone	Death D91, cerebral toxoplasmosis
2	43	Ph⁺ALL	CR1	Yes	—	—	—	Death D129, ALL relapse
3	38	HG B-cell lymphoma	Refractory relapse	Yes	D15	III	CR GCV alone	Death D106, refractory lymphoma
4	49	Myelodysplasia	Refractory	Yes	—	—	—	Death D38, posttraumatic cerebral hemorrhage
5	52	HG B-cell lymphoma	CR2	Yes	—	—	—	Death D72, EBV-LPD + lung aspergillosis
6	41	CML	CP	Yes	D20	II	CR GCV + steroids	Alive 34 months +, CR
7	51	Ph⁺ALL	CR1	Yes, late graft failure^*	—	—	—	Alive 34 months +, CR^†
8	43	CML	CP	Yes	—	—	—	Alive 29 months +, CR
9	43	CML	CP	Yes	D135 CGVHD	—	CR GCV alone^‡	Alive 31 months +, CR^1-153
10	46	CML	CP	Yes, late graft failure^1-155	—	—	—	Death D159, EBV-lymphoma^1-155
11	49	HG B-cell lymphoma	Refractory	Yes	—	—	—	Death D252, acute GVHD^1-154
12	55	Waldenström disease	Refractory	Yes	D40	I#	CR GCV alone	Death D300, sepsis

HG indicates high grade; D, day; CR, complete remission; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; CP, chronic phase; and CGVHD, chronic GVHD.

Second allogeneic transplantation from the same donor (ATG conditioning regimen, unmanipulated BMT) on day 301 because of late graft failure.

†

Intermittent presence of amino bcr/abl mRNA transcript in PBMCs.

‡

Concomitant Ig infusion.

F1-153

Chronic GVHD after nongene-modified donor lymphocyte infusion for cytogenetic relapse 2 years after transplantation.

F1-155

Second allogeneic transplantation (cyclosphosphamide plus ATG conditioning regimen, unmanipulated G-CSF–mobilized peripheral blood graft) on day 152 because of late graft failure.

F1-154

Refractory grade IV acute GVHD after infusion of non–gene-modified donor lymphocyte infusion for lymphoma relapse.

#GCV treatment of grade I acute GVHD because of a concomitant CMV lung infection.

View Large

This Feature Is Available To Subscribers Only